阿普米司特对银屑病关节炎患者手部及全身MRI炎症评估的影响(MOSAIC):一项4期、多中心、单臂、开放标签研究
MOSAIC是一项4期、多中心、单臂、开放标签研究,在10个国家29个中心纳入122例接受阿普米司特30 mg每日两次治疗的银屑病关节炎患者。第24周时,PsAMRIS评估的骨水肿、滑膜炎和腱鞘炎复合炎症评分较基线的最小二乘均值变化为-2.32(95%CI -4.73至0.09)。作者认为阿普米司特改善了手部和全身MRI评估的关节及附着点炎症。
要点
- 第24周PsAMRIS复合炎症评分较基线的最小二乘均值变化为-2.32(95%CI -4.73至0.09)。
- 122例患者中95例(78%)发生至少1例治疗中出现的不良事件。
- 6例(5%)发生严重治疗中出现的不良事件,6例(5%)发生重度治疗中出现的不良事件。
核心结论
- 作者认为阿普米司特改善了手部和全身MRI评估的关节及附着点炎症。
- 作者认为研究结果鼓励在银屑病关节炎临床试验中使用MRI(包括全身MRI)作为客观结局指标。
研究设计与样本
- MOSAIC为4期、多中心、单臂、开放标签研究,在10个国家(比利时、加拿大、丹麦、德国、意大利、俄罗斯、西班牙、瑞士、英国和美国)的29个中心开展。
- 纳入18岁及以上、银屑病关节炎诊断病程3个月至5年、符合活动性银屑病关节炎分类标准、至少有3个肿胀关节和3个压痛关节且伴手部受累、至少1个活动性附着点炎部位的患者。
- 排除既往使用生物改善病情抗风湿药或既往使用超过2种传统合成改善病情抗风湿药的患者。
- 经过5天滴定期后,患者接受阿普米司特30 mg口服每日两次;允许联用稳定剂量甲氨蝶呤至每周25 mg。
- 全分析集和安全人群包括所有入组且至少接受1剂阿普米司特的患者;2019年2月6日至2022年5月11日期间入组123例患者,其中122例(99%)接受治疗并纳入分析。
主要发现
- 122例患者中67例(55%)为女性、55例(45%)为男性、116例(95%)为白人;80例(66%)完成48周治疗。
- 第24周PsAMRIS评估的骨水肿、滑膜炎和腱鞘炎复合炎症评分较基线的最小二乘均值变化为-2.32(95%CI -4.73至0.09)。
- 122例患者中95例(78%)发生至少1例治疗中出现的不良事件。
- 6例(5%)患者发生重度治疗中出现的不良事件,6例(5%)患者发生严重治疗中出现的不良事件。
- 未发生被认为与阿普米司特相关的严重治疗中出现的不良事件。
关键数值与推荐
- 主要终点为第24周PsAMRIS评估的手部骨水肿、滑膜炎和腱鞘炎复合炎症评分较基线的变化,最小二乘均值变化为-2.32(95%CI -4.73至0.09)。
- 阿普米司特给药方案为经过5天滴定期后30 mg口服每日两次。
- 允许联用稳定剂量甲氨蝶呤至每周25 mg。
临床怎么用
- 作者认为研究结果鼓励在银屑病关节炎临床试验中使用MRI(包括全身MRI)作为客观结局指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS) and MRI Whole-Body Scoring System for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis (MRI-WIPE) have not been used together to assess treatment of psoriatic arthritis in a clinical trial. We aimed to assess the effect of apremilast treatment on inflammation, with outcomes measured by PsAMRIS and MRI-WIPE. METHODS: MOSAIC was a phase 4, multicentre, single-arm, open-label study conducted at 29 sites across ten countries (Belgium, Canada, Denmark, Germany, Italy, Russia, Spain, Switzerland, the UK, and the USA). Adults aged 18 years or older with a documented diagnosis of psoriatic arthritis for a duration of 3 months to 5 years self-enrolled and were included if they met the classification criteria for active psoriatic arthritis at screening. Patients were required to have at least three swollen and three tender joints with hand involvement and at least one active enthesitis site according to the Spondyloarthritis Research Consortium of Canada enthesitis index or the Leeds enthesitis index. Patients were excluded if they had previous treatment with a biological disease-modifying antirheumatic drug or previous treatment with more than two conventional synthetic disease-modifying antirheumatic drugs. After a 5-day titration period, patients received apremilast 30 mg orally twice per day. Concomitant stable methotrexate up to 25 mg per week was permitted. The primary endpoint was change from baseline to week 24 in a composite inflammation score of bone marrow oedema, synovitis, and tenosynovitis in the hand as assessed by PsAMRIS. The full analysis set and safety population included all enrolled patients who received at least one dose of apremilast. This completed study is registered with ClinicalTrials.gov (NCT03783026). FINDINGS: Between Feb 6, 2019, and May 11, 2022, 123 patients were enrolled in the MOSAIC study. Of these 123 patients, 122 (99%) were treated with apremilast and included in the full analysis set and safety population. 67 (55%) of 122 patients were female, 55 (45%) were male, and 116 (95%) were White. 80 (66%) of 122 patients completed 48 weeks of treatment. The least squares mean change from baseline to week 24 in the composite inflammation score of bone marrow oedema, synovitis, and tenosynovitis as assessed by PsAMRIS was -2·32 (95% CI -4·73 to 0·09). 95 (78%) of 122 patients had at least one treatment-emergent adverse event. Six (5%) patients had a severe treatment-emergent adverse event and six (5%) patients had a serious treatment-emergent adverse event. No serious treatment-emergent adverse events were considered to be related to apremilast. INTERPRETATION: Apremilast improved inflammation in joints and entheses on assessment of MRI measures in the hand and the whole body. Our findings encourage the use of MRI, including whole-body MRI, as an objective outcome measure in trials in patients with psoriatic arthritis. FUNDING: Amgen.
引用
- Østergaard M, Boesen M, Maksymowych WP, et al. Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study. Lancet Rheumatol. 2024. PMID: 39488216. doi:10.1016/S2665-9913(24)00232-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。